Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. In vitro binding activity of murine T cell BsAb panel.
  • Fig. S2. In vivo tumor responses using EAT xenograft tumor model.
  • Fig. S3. In vivo tumor responses using syngeneic tumor model.
  • Fig. S4. In vitro coculture assay analysis.
  • Fig. S5. Naïve T cell activation by dual bivalent BsAb formats.
  • Fig. S6. In vivo tumor responses using EAT xenograft tumor model.
  • Fig. S7. In vitro conjugate assay analysis.
  • Fig. S8. T cell activation using the IgG-[L]-scFv panel.
  • Fig. S9. In vivo tumor responses using syngeneic tumor model.
  • Table S1. In vitro properties and design of anti-GD2 BsAb.
  • Table S2. GD2 binding kinetics for BsAb using SPR.
  • Table S3. huCD3ε binding kinetics for BsAb using SPR.
  • Table S4. In vitro properties and design of additional anti-GD2 BsAb.
  • Table S5. muCD3ε binding kinetics for BsAb using SPR.
  • Table S6. In vivo pharmacokinetics of 2+2 BsAb.
  • Table S7. In vitro properties and design of dual bivalent BsAb.
  • Table S8. In vitro properties and design of anti-GD2 IgG-[L]-scFv panel.
  • Table S9. GD2 binding kinetics for IgG-[L]-scFv panel using SPR.
  • Table S10. huCD3ε binding kinetics for IgG-[L]-scFv panel using SPR.
  • Table S11. In vitro properties and design of anti-CD33 IgG-[L]-scFv panel.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: